On Apr. 23, 2021, Inovio Pharma announced that it was planning for a predominantly ex-U.S. Phase 3 trial for its COVID-19 vaccine candidate, INO-4800.

Given the increasing availability of vaccines authorized for emergency use, the Department of Defense announced that was discontinuing funding for the Phase 3 segment of the INNOVATE trial, while continuing to fund the completion of the ongoing Phase 2 segment.